25-hydroxy cholecalciferol in newly diagnosed pulmonary tuberculosis patients

The present study was conducted to evaluate 25 hydroxy cholecalciferol levels in newly diagnosed pulmonary tuberculosis patients. Comparative case control study. Department of Medicine, Liaquat University of Medical and Health Sciences Hospital Jamshoro/Hyderabad, from February to October 2015. 100 diagnosed cases of pulmonary tuberculosis and 100 age and gender matched controls were selected according to criteria. 5 ml of venous blood sample was collected and centrifuged at 4000rpm for 10 minutes. The serum obtained was frozen at -20 o C and used for estimation of 25hydroxycholecalciferolon ARCHITECT I 1000 system. The data was analyzed on SPSS version 22.0 at 95% confidence interval (p ≤ 0.05). Total mean± S.D of 25hydroxycholecalciferol was noted as 26.1±9.76 and 38.8±7.14 (ng/dl) in cases and controls respectively (p=0.0001). 25-hydroxycholecalciferol <5.4 ng/dl was noted in the tuberculosis cases. Normal, insufficiency and deficiency of 25-hydroxycholecalciferol was noted in 17%, 19% and 64% & 56%, 18% and 26% of cases and controls respectively (p< 0.01). The present study reports significantly low 25hydroxycholecalciferol in pulmonary tuberculosis cases. However further studies are warranted. Pulmonary tuberculosis patients may be supplemented with vitamin D. © 2016 Elixir All rights reserved. Elixir Physio. & Anatomy 95 (2016) 41159-41162 Physiology and Anatomy Available online at www.elixirpublishers. com (Elixir International Journal) Mohsin Rajput et al./ Elixir Physio. & Anatomy 95 (2016) 41159-41162 41160 during last three months and smokers were excluded from the study. All subjects were screened by a medical officer and were diagnosed by a consultant physician or a chest specialist. 5 ml of venous blood sample was collected and centrifuged at 4000rpm for 10 minutes. The serum obtained was frozen at 20 o C and used for estimation of 25-hydroxycholecalciferolon ARCHITECT I 1000 system. Institutional ethical approval was taken. Informed consent form was signed by each willing participant. Patient’s data was noted on a pre-structured proforma. Confidentially of patients information was ensured. The data was analyzed on SPSS version 22.0. Student’s t test and chi square test was used for continuous and categorical data respectively at 95% confidence interval (p ≤ 0.05). Results Cases and controls showed mean ± S.D age of 49 ±6.7 and 48.1± 5.6 years respectively. The baseline characteristics of cases and controls are shown in table 1. Age and gender distribution showed non-significant (p>0.05) differences. BMI revealed low body weight of cases. Tuberculosis cavity was noted in 69 (69%) of cases. Complete blood counts showed low hemoglobin and red blood cell counts in the cases compared to controls (p< 0.05). Alkaline phosphatase, serum calcium & phosphate, blood urea nitrogen and serum creatinine were evaluated at baseline as shown in table 1. Total mean± S.D 25-hydroxycholecalciferol was noted as 26.1±9.76 and 38.8±7.14 (ng/dl) in cases and controls respectively (p=0.0001). 25-hydroxycholecalciferol less than 5.4 ng/dl was noted in the cases. Table 2 shows the normal, insufficiency and deficiency of 25-hydroxycholecalciferol in cases and controls. Graph 1 shows the normal, insufficiency and deficiency of 25-hydroxycholecalciferol in 17%, 19% and 64% & 56%, 18% and 26% of cases and controls respectively (p< 0.01). Table 1. Characteristics of cases and control subjects.